Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission

Elias J. Jabbour, Fadi G. Haddad, Nicholas J. Short, Jayastu Senapati, Nitin Jain, Koji Sasaki, Jeffrey L Jorgensen, Sa A. Wang, Yesid Alvarado, Xuemei Wang, Courtney D DiNardo, Lucia Masarova, Tapan M. Kadia, Rebecca Garris, Farhad Ravandi, Hagop M Kantarjian

Blood blood.2023022330.

https://doi.org/10.1182/blood.2023022330

Published: 2023

Includes: Supplemental data

Journal Articles

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 2267–2269.

https://doi.org/10.1182/blood-2022-162892

Published: 2022

Journal Articles

The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency

Blood (2022) 140 (Supplement 1): 6306–6308.

https://doi.org/10.1182/blood-2022-164494

Published: 2022

Journal Articles

Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study

Blood (2022) 140 (Supplement 1): 11698–11701.

https://doi.org/10.1182/blood-2022-170049

Published: 2022

Journal Articles

Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia

Tareq Abuasab, Fadi Haddad, Shehab Fareed Mohamed, Jeffrey L. Jorgensen, Sa A Wang, Philip A. Thompson, Tapan M. Kadia, Yesid Alvarado, Sherry A. Pierce, Michael J. Keating, David McCue, Hagop Kantarjian, Farhad Ravandi

Blood (2022) 140 (Supplement 1): 9385–9386.

https://doi.org/10.1182/blood-2022-165639

Published: 2022

Journal Articles

Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Blood (2022) 140 (Supplement 1): 1702–1704.

https://doi.org/10.1182/blood-2022-167931

Published: 2022

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

Blood (2022) 140 (Supplement 1): 234–237.

https://doi.org/10.1182/blood-2022-170850

Published: 2022

Journal Articles

Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission

Blood (2022) 140 (Supplement 1): 543–545.

https://doi.org/10.1182/blood-2022-156955

Published: 2022

Journal Articles

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans-Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso-Ramos, Jorge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Hervé Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gökbuget, Jason Gotlib, Eva Hellström-Lindberg, Gabriela S. Hobbs, Ronald Hoffman, Elias J. Jabbour, Jean-Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L.-C. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte Niemeyer, Olatoyosi M. Odenike, Seishi Ogawa, Alberto Orfao, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching-Hon Pui, Jerald P. Radich, Andreas Reiter, Maria Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt-Graeff, Akiko Shimamura, Jorge Sierra, Wendy A. Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei-Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi

Blood (2022) 140 (11): 1200–1228.

https://doi.org/10.1182/blood.2022015850

Published: 2022

Includes: Supplemental data

Journal Articles

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Blood (2021) 138 (Supplement 1): 3363.

https://doi.org/10.1182/blood-2021-154155

Published: 2021

Journal Articles

Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Blood (2021) 138 (Supplement 1): 3400.

https://doi.org/10.1182/blood-2021-154074

Published: 2021

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results

Blood (2021) 138 (Supplement 1): 3720.

https://doi.org/10.1182/blood-2021-154454

Published: 2021

Journal Articles

Oligoblastic (<20%) Myeloid Neoplasms with KMT2A ( MLL ) Rearrangement Show Significant Overlap with Acute Myeloid Leukemia (AML) and Should be Regarded As AML

Sergej Konoplev, Guilin Tang, Xiaoqiong Wang, Wei Wang, Beenu Thakral, Jie Xu, Sherry A. Pierce, Jeffrey L. Jorgensen, Farhad Ravandi, Ghayas C. Issa, Olga Pozdnyakova, Sa A Wang, Robert P. Hasserjian

Blood (2021) 138 (Supplement 1): 793.

https://doi.org/10.1182/blood-2021-153749

Published: 2021

Journal Articles

Prognostic Value of Measurable Residual Disease Assessed By Multiparameter Flowcytometry in Patients with NPM1-Mutated Acute Myeloid Leukemia

Sangeetha Venugopal, Nicholas J. Short, Jeffrey L. Jorgensen, Tapan M. Kadia, Courtney D. DiNardo, Marina Konopleva, Sherry A. Pierce, Sanam Loghavi, Keyur P. Patel, Ghayas C. Issa, Hagop Kantarjian, Sa A Wang, Farhad Ravandi

Blood (2021) 138 (Supplement 1): 2374.

https://doi.org/10.1182/blood-2021-154105

Published: 2021

Journal Articles

Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 701.

https://doi.org/10.1182/blood-2021-150457

Published: 2021

Journal Articles

In Depth Analysis of Blastic Plasmacytoid Dendritic Cell Neoplasm Based on a Comprehensive Literature Database of Cases

Robert S. Ohgami, Phyu Aung, Alejandro Ariel Gru, Mohammad O Hussaini, Christiane Querfeld, Kelou Yao, Corinn Small, Sumanth Gollapudi, David L Jaye, Sa A Wang, Sheeja T Pullarkat, Tracy I. George

Blood (2021) 138 (Supplement 1): 4383.

https://doi.org/10.1182/blood-2021-151694

Published: 2021

Journal Articles

Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Blood (2021) 138 (Supplement 1): 1233.

https://doi.org/10.1182/blood-2021-154022

Published: 2021

Journal Articles

Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML

Curtis Lachowiez, Courtney D. DiNardo, Kiyomi Morita, Ken Furudate, Feng Wang, Tomoyuki Tanaka, Sa A Wang, Tapan M. Kadia, Naval Daver, Nicholas J. Short, Joseph D. Khoury, Keyur Patel, L. Jeffrey Medeiros, Marina Konopleva, Farhad Ravandi, Koichi Takahashi, Sanam Loghavi

Blood (2021) 138 (Supplement 1): 607.

https://doi.org/10.1182/blood-2021-148971

Published: 2021

Journal Articles

Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia

Blood (2021) 138 (18): 1733–1739.

https://doi.org/10.1182/blood.2020010483

Published: 2021

Includes: Supplemental data

Journal Articles

Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Blood (2020) 136 (Supplement 1): 18–20.

https://doi.org/10.1182/blood-2020-134300

Published: 2020

NARROW

Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency

Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study

Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia

Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results

Oligoblastic (<20%) Myeloid Neoplasms with KMT2A ( MLL ) Rearrangement Show Significant Overlap with Acute Myeloid Leukemia (AML) and Should be Regarded As AML

Prognostic Value of Measurable Residual Disease Assessed By Multiparameter Flowcytometry in Patients with NPM1-Mutated Acute Myeloid Leukemia

Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia

In Depth Analysis of Blastic Plasmacytoid Dendritic Cell Neoplasm Based on a Comprehensive Literature Database of Cases

Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML

Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia

Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only